Featuring the release of the ISMPP open access white paper, the threat of predatory publishers to the student community and the opinions of faculty members on open access publishing models
Blog
Weekly digest: what’s happening in open science?
Featuring the drive towards restructuring academic publishing, an exciting new deal for Cambridge University Press and Plan S feedback and resources
Weekly digest: what’s happening in open science?
Featuring the release of the latest European University Association Open Access Survey results, the ordering of a predatory publisher to pay millions of dollars for deception, the adoption of Creative Commons licences by the European Commission and the launch of PeerJ-SciHub.
Weekly digest: what’s happening in open science?
Featuring controversial new EU online copyright legislation, an opinion piece on gold open access and Plan S published in the NEJM, a partnership between Kudos and DataCite and Open Pharma educational materials on open access
New Open Pharma resource: open access educational materials
New Open Pharma resource: open access educational materials
Weekly digest: what’s happening in open science?
Featuring comments from the co-chair of cOAlition S, draft recommendations from the MIT Open Access Task Force, strategies to break the academic status quo, and the need for research transparency
Weekly digest: what’s happening in open science?
Featuring the lost science of the 1990s, a country-wide boycott of Elsevier subscriptions, plans to help society publishers embrace Plan S and the validity of preprints
Weekly digest: what’s happening in open science?
Featuring the University of California’s split from Elsevier, opinions on Plan S from the Global South and the academic community and the rise in pharma research published open access
Using metadata to make open access science discoverable
In January 2019, Open Pharma core members and supporters attended a roundtable meeting, hosted by The BMJ at its Head Office at BMA House in London.
Weekly digest: what’s happening in open science?
Featuring changes to clinical trial reporting and data sharing regulations, and criticism of Plan S from the perspective of highly selective subscription journals